Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment. Read More ›

Treatment with ribociclib and an aromatase inhibitor or fulvestrant for hormone receptor–positive, HER2-negative metastatic breast cancer did not increase the risk of thrombosis in the real-world setting. Read More ›

Palbociclib combined with letrozole is associated with improved outcomes for patients with hormone receptor–positive, HER2-negative metastatic breast cancer with lung or liver metastases in the first-line setting Read More ›

Study results reinforce that patient selection for abemaciclib treatment is critical to ensure adequate efficacy and safety. Read More ›

During active chemotherapy treatment, adopting an aerobic exercise program may reduce cancer-related fatigue. Read More ›

Patient outcomes could be improved through targeted education for oncology nurses focused on managing treatment-related adverse events. Read More ›

A new landmark study, MONALEESA-3, demonstrates extended overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Read More ›

Nurses play a significant role in addressing the challenges of monitoring nutrition in cancer patients. Read More ›

Personalized, risk-adapted breast cancer screening may establish a new category of screening appropriate for low-risk patients for whom less-intensive screening is sufficient. Read More ›

Compelling efficacy data for sacituzumab govitecan-hziy results in FDA fast-track approval for its use in metastatic triple-negative breast cancer. Read More ›